Drug updated on 11/14/2023
|Tablet (oral:100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor, co-packaged with 150 mg ivacaftor)
| Ongoing and
- For the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
Product Monograph / Prescribing Information
|Trikafta (elexacaftor, ivacaftor, and tezacaftor) Prescribing Information.
|Vertex Pharmaceuticals Inc., Boston, MA
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Canadian clinical consensus guideline for initiation, monitoring and discontinuation of CFTR modulator therapies for patients with cystic fibrosis.
|Cystic Fibrosis Canada